PT - JOURNAL ARTICLE AU - Peter Grendelmeier AU - Werner Strobel AU - Thomas Schmid AU - Kathleen Jahn AU - Michael Tamm AU - Daiana Stolz TI - Vasopressin in patients with obstructive sleep apnoea syndrome – An interventional, case-control study DP - 2014 Sep 01 TA - European Respiratory Journal PG - P1747 VI - 44 IP - Suppl 58 4099 - http://erj.ersjournals.com/content/44/Suppl_58/P1747.short 4100 - http://erj.ersjournals.com/content/44/Suppl_58/P1747.full SO - Eur Respir J2014 Sep 01; 44 AB - Background Hypoxia, sympathetic activation, vascular endothelial dysfunction, metabolic dysregulation, oxidative stress as well as inflammation play a role in the development of cardiovascular disease in OSAS and are related to the release of vasopressin (AVP). We hypothesize that AVP might serve as a potential proxy for prognosis and therapy response in OSAS.Methods 289 patients with suspicion of OSAS undergoing a diagnostic work-up were included in this prospective, interventional, longitudinal, case-control study. The primary endpoint was the change in AVP levels after 1 month of CPAP treatment. Secondary endpoints included 1) circulating AVP levels before treatment and after 1 and 6 months of treatment respectively; 2) change in circulating AVP levels after 1 night and 6 months of CPAP treatment respectively; 3) assessment of endpoints in subgroups of patients according to OSAS severity.Results 243 patients with OSAS (age 55.0 ± 13.0 years, 77.8 % male, BMI 31.2 ± 5.6) and 46 controls without OSAS (age 51.2 ± 14.2 years, 50 % male, BMI 30.7 ± 5.8) were analysed. Mean ODI of patients with OSAS was 18 / h ± 15, mean AHI was 17 / h ± 15. 87.9 % of patients with OSAS started cPAP therapy. After 1 month, 85.1 % of patients with OSAS were on cPAP therapy. There was no significant difference in the slope of change of the AVP level between patients and controls and between OSAS patients with or without CPAP therapy. After adjustment for severity of OSAS, comorbidities and duration of CPAP therapy in minutes the differences remained non-statistically significant.Conclusions Vasopressin cannot be used as a proxy for prognosis and therapy response in obstructive sleep apnoea syndrome.